Sara Pisani is Trial Coordinator for the CAN-PDP trial at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. 

Research Interests

• Parkinson’s Disease
• Non-motor symptoms of Parkinson’s Disease
• Clinical Trials
• Cognitive Impairments
• Neuroimaging

Key Publications

Pisani, S., Gosse, L., Aarsland, D., Ray Chaudhuri, K., Ballard, C., Ffytche, D., Velayudhan, L., & Bhattacharyya, S. (2024). Parkinson's disease psychosis associated with accelerated multidomain cognitive decline. BMJ mental health, 27(1), 1–10. https://doi.org/10.1136/bmjment-2024-301062

Velayudhan, L., Dugonjic, M., Pisani, S., Harborow, L., Aarsland, D., Bassett, P., & Bhattacharyya, S. (2024). Cannabidiol for behavior symptoms in Alzheimer’s disease (CANBiS-AD): a randomized, double-blind, placebo-controlled trial. International Psychogeriatrics, 1–3. doi:10.1017/S1041610224000516

Pisani, S., Gosse, L., Wieretilo, R., Ffytche, D., Velayudhan, L., & Bhattacharyya, S. (2024). Cognitive and executive impairments in Parkinson’s disease psychosis: a Bayesian meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry, 95(3), 277-287.

Pisani, S., Gunasekera, B., Lu, Y., Vignando, M., Aarsland, D., Chaudhuri, K. R., ... & Bhattacharyya, S. (2023). Grey matter volume loss in Parkinson’s Disease Psychosis and its relationship with serotonergic gene expression: A meta-analysis. Neuroscience & Biobehavioral Reviews, 147, 105081.

Pisani, S., Murphy, J., Conway, J., Millgate, E., Catmur, C., & Bird, G. (2021). The relationship between alexithymia and theory of mind: A systematic review. Neuroscience & Biobehavioral Reviews, 131, 497-524.

Pisani, S., McGoohan, K., Velayudhan, L. et al. Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Drugs Aging 38, 887–910 (2021). https://doi.org/10.1007/s40266-021-00882-2

Pisani, S., Mueller, C., Huntley, J., Aarsland, D., & Kempton, M. J. (2021). A meta‐analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil. International journal of geriatric psychiatry, 36(10), 1471-1487.